{
    "id": "dbpedia_2235_2",
    "rank": 48,
    "data": {
        "url": "https://www.oncotarget.com/article/28233/text/",
        "read_more_link": "",
        "language": "en",
        "title": "Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach",
        "top_image": "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072026",
        "meta_img": "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072026",
        "images": [
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072026",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072027",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072028",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072029",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072030",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072031",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072032",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072033",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072034",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072040",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072041",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072042",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072043",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072044",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072045",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072046",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072035",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072036",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072037",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072038",
            "https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=28233&path%5B%5D=95418&path%5B%5D=1072039",
            "https://www.oncotarget.com/images/80x15.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "non-small cell lung cancer; miRNAs; miR-520c-3p; PI3K/AKT signaling pathway; therapeutic targeting"
        ],
        "tags": null,
        "authors": [
            "Pooja Gulhane",
            "Prajakta Nimsarkar",
            "Komal Kharat",
            "Shailza Singh"
        ],
        "publish_date": "2022-01-01T00:00:00",
        "summary": "",
        "meta_description": "https://doi.org/10.18632/oncotarget.28233 Pooja Gulhane, Prajakta Nimsarkar, Komal Kharat, Shailza Singh",
        "meta_lang": "en",
        "meta_favicon": "https://www.oncotarget.com/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.oncotarget.com/article/28233/text/",
        "text": "Conclusions\n\nIn this study, miR-520c-3p was a new tumor suppressor miRNA identified in NSCLC. The heatmap analysis revealed that it might have a functional role in NSCLC by targeting the defective EGFR and PI3K/AKT-driven signaling pathway. AKT1 and AKT2 were identified as possible targets of miR-520c-3p based on target prediction and seed sequence analysis. AKT’s promote biological activities such as protein synthesis, glucose metabolism, cell cycle progression, anti-apoptosis, angiogenesis, and lymphangiogenesis, which are necessary for tumor cell survival, proliferation, metastasis, and invasion. AKT has also been discovered to affect the tumor suppressor function of p53 indirectly. miR-520c-3p can regulate the overexpression of AKT genes and their downstream processing in the EGFR pathway, triggering death in tumor cells, restoring the function of tumor suppressor p53, and decreasing protein synthesis for cell survival. The Cancer Genome Atlas (TCGA) database data revealed a negative association between AKT1, AKT2, and miR-520c-3p mRNA levels. Elevating the expression of miR-520c-3p in a regulated manner using a developed genetic synthetic circuit is novel as an RNA therapy might help suppress tumors in NSCLC in the future by blocking PI3K/AKT/MTOR signaling pathway in a controlled manner.\n\nAbbreviations\n\nALK: Anaplastic lymphoma kinase; COPASI: Complex Pathway Simulator; ROS1: c-ros oncogene 1; ES: Enrichment score; EGFR: Epidermal growth factor receptor; GRENITS: Gene Regulatory Network Inference Using Time Series; mTOR: Mechanistic target of rapamycin; NSCLC: Non-small cell lung cancer; PI3K: Phosphatidylinositol-3-kinase.\n\nReferences\n\n1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011; 378:1727–40. https://doi.org/10.1016/S0140-6736(10)62101-0. [PubMed].\n\n2. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553:446–54. https://doi.org/10.1038/nature25183. [PubMed].\n\n3. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015; 4:36–54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01. [PubMed].\n\n4. Ye Z, Huang Y, Ke J, Zhu X, Leng S, Luo H. Breakthrough in targeted therapy for non-small cell lung cancer. Biomed Pharmacother. 2021; 133:111079. https://doi.org/10.1016/j.biopha.2020.111079. [PubMed].\n\n5. Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021; 22:612. https://doi.org/10.3390/ijms22020612. [PubMed].\n\n6. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014; 9:287–314. https://doi.org/10.1146/annurev-pathol-012513-104715. [PubMed].\n\n7. Fabbri M. MicroRNAs and cancer: towards a personalized medicine. Curr Mol Med. 2013; 13:751–56. https://doi.org/10.2174/1566524011313050006. [PubMed].\n\n8. Faversani A, Amatori S, Augello C, Colombo F, Porretti L, Fanelli M, Ferrero S, Palleschi A, Pelicci PG, Belloni E, Ercoli G, Degrassi A, Baccarin M, et al. miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget. 2017; 8:7231–47. https://doi.org/10.18632/oncotarget.13933. [PubMed].\n\n9. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8:S11. https://doi.org/10.1186/1752-0509-8-S4-S11. [PubMed].\n\n10. Otasek D, Morris JH, Bouças J, Pico AR, Demchak B. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019; 20:185. https://doi.org/10.1186/s13059-019-1758-4. [PubMed].\n\n11. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014; 42:609–21. https://doi.org/10.1093/nar/gkt852. [PubMed].\n\n12. Guan P, Yin Z, Li X, Wu W, Zhou B. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012; 31:54. https://doi.org/10.1186/1756-9966-31-54. [PubMed].\n\n13. Liao J, Shen J, Leng Q, Qin M, Zhan M, Jiang F. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC). Thorac Cancer. 2020; 11:762–68. https://doi.org/10.1111/1759-7714.13337. [PubMed].\n\n14. Snow A, Ring A, Struycken L, Mack W, Koç M, Lang JE. Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites. Cancer Epidemiol. 2021; 70:101857. https://doi.org/10.1016/j.canep.2020.101857. [PubMed].\n\n15. He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y, Wang X. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci. 2020; 16:2628–47. https://doi.org/10.7150/ijbs.47203. [PubMed].\n\n16. Mitra R, Adams CM, Jiang W, Greenawalt E, Eischen CM. Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival. Nat Commun. 2020; 11:968. https://doi.org/10.1038/s41467-020-14713-2. [PubMed].\n\n17. Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol. 2020; 13:25. https://doi.org/10.1186/s13045-020-00848-8. [PubMed].\n\n18. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005; 21:3448–49. https://doi.org/10.1093/bioinformatics/bti551. [PubMed].\n\n19. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma’ayan A. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44:W90–97. https://doi.org/10.1093/nar/gkw377. [PubMed].\n\n20. Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, Wadi L, Meyer M, Wong J, Xu C, Merico D, Bader GD. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc. 2019; 14:482–517. https://doi.org/10.1038/s41596-018-0103-9. [PubMed].\n\n21. Nimsarkar P, Ingale P, Singh S. Systems Studies Uncover miR-146a as a Target in Leishmania major Infection Model. ACS Omega. 2020; 5:12516–26. https://doi.org/10.1021/acsomega.0c01502. [PubMed].\n\n22. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015; 12:115–21. https://doi.org/10.1038/nmeth.3252. [PubMed].\n\n23. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010; 5:e13984. https://doi.org/10.1371/journal.pone.0013984. [PubMed].\n\n24. Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G, Bertolotti R, Bellomi M, Rampinelli C, Maisonneuve P, Spaggiari L, Veronesi G, Nicassio F, et al. miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst. 2015; 107:djv063. https://doi.org/10.1093/jnci/djv063. [PubMed].\n\n25. Oliveira AC, Bovolenta LA, Nachtigall PG, Herkenhoff ME, Lemke N, Pinhal D. Combining Results from Distinct MicroRNA Target Prediction Tools Enhances the Performance of Analyses. Front Genet. 2017; 8:59. https://doi.org/10.3389/fgene.2017.00059. [PubMed].\n\n26. Saumet A, Mathelier A, Lecellier CH. The potential of microRNAs in personalized medicine against cancers. Biomed Res Int. 2014; 2014:642916. https://doi.org/10.1155/2014/642916. [PubMed].\n\n27. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13:2498–504. https://doi.org/10.1101/gr.1239303. [PubMed].\n\n28. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La Vecchia C, Pastorino U. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014; 32:768–73. https://doi.org/10.1200/JCO.2013.50.4357. [PubMed].\n\n29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–50. https://doi.org/10.1073/pnas.0506580102. [PubMed].\n\n30. Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC, Reimand J, and PCAWG Drivers and Functional Interpretation Working Group, and PCAWG Consortium. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020; 11:735. https://doi.org/10.1038/s41467-019-13983-9. [PubMed].\n\n31. Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020; 11:511–18. https://doi.org/10.1111/1759-7714.13328. [PubMed].\n\n32. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T, Hatzigeorgiou AG. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015; 43:W460–66. https://doi.org/10.1093/nar/gkv403. [PubMed].\n\n33. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71:7–33. https://doi.org/10.3322/caac.21654. [PubMed].\n\n34. Yuan Y, Du W, Wang Y, Xu C, Wang J, Zhang Y, Wang H, Ju J, Zhao L, Wang Z, Lu Y, Cai B, Pan Z. Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer. Int J Cancer. 2015; 136:1333–40. https://doi.org/10.1002/ijc.29103. [PubMed].\n\n35. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27:91–105. https://doi.org/10.1016/j.molcel.2007.06.017. [PubMed].\n\n36. Gao J, Ren Y, Guo H, Mao R, Xie H, Su H, She Y, Deng J, Yang M, Han B, Zhang Y, Li J, Xie D, Chen C. A new method for predicting survival in stage I non-small cell lung cancer patients: nomogram based on macrophage immunoscore, TNM stage and lymphocyte-to-monocyte ratio. Ann Transl Med. 2020; 8:470. https://doi.org/10.21037/atm.2020.03.113. [PubMed].\n\n37. Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, Liang H. Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res. 2017; 77:e51–54. https://doi.org/10.1158/0008-5472.CAN-17-0369. [PubMed].\n\n38. Cai L, Lin S, Girard L, Zhou Y, Yang L, Ci B, Zhou Q, Luo D, Yao B, Tang H, Allen J, Huffman K, Gazdar A, et al. LCE: an open web portal to explore gene expression and clinical associations in lung cancer. Oncogene. 2019; 38:2551–64. https://doi.org/10.1038/s41388-018-0588-2. [PubMed].\n\n39. Chandran D, Bergmann FT, Sauro HM. Computer-aided design of biological circuits using TinkerCell. Bioeng Bugs. 2010; 1:274–81. https://doi.org/10.4161/bbug.1.4.12506. [PubMed]."
    }
}